stage III or IV lung cancer, any-stage pancreatic cancer, unresectable cholangiocarcinoma, unresectable liver cancer, unresectable ampullary or peri-ampullary cancer or other stage IV gastrointestinal cancer, stage III or IV ovarian and fallopian tube cancers or other stage IV gynecologic cancer, stage IV breast cancer, genitourinary cancer, sarcoma, melanoma, or endocrine cancer.
Conditions
Interventions
Participants and therapists will have 3-6 individual therapy sessions, each approximately 45-60 minutes in length, delivered over 3-6 months (the number of sessions may vary, depending on the clinical
Sponsors
The University Tokyo Hospital
the Cancer Institute Hospital of Japanese Foundation for Cancer Research, and Yamaguchi University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The following inclusion criteria must be fulfilled among outpatients who will receive CALM therapy as their usual treatment. 1.Aged 18 and over 2.be fluent in spoken Japanese 3.be able to provide informed consent 4.have received a diagnosis of stage III or IV lung cancer, any-stage pancreatic cancer, unresectable cholangiocarcinoma, unresectable liver cancer, unresectable ampullary or peri-ampullary cancer or other stage IV gastrointestinal cancer, stage III or IV ovarian and fallopian tube cancers or other stage IV gynecologic cancer, stage IV breast cancer, genitourinary cancer, sarcoma, melanoma, or endocrine cancer, and have an understanding of their diagnosis. 5.Expected survival is 6 months or more.
Exclusion criteria
Exclusion criteria: 1.Major communication difficulties with therapist 2.Inability to commit to the required 3-6 psychotherapy sessions, for example, too ill to participate, lack of transportation, insufficient motivation to participate, etc. 3.Cognitive impairment as indicated by the clinical team or in the patient's chart 4.Cases in which the therapist indicates pharmacotherapy as a priority treatment for the patient during the first interview.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement rate of depressive symptoms using the PHQ-9 and completion rate | — |
Secondary
| Measure | Time frame |
|---|---|
| The Quality of Life at the End of Life-Cancer Scale (QUAL-EC), The Death and Dying Distress Scale (DADDS), Experiences in Close Relationships (ECR-M16), The Clinical Evaluation Questionnaire (CEQ) | — |
Countries
Japan
Contacts
Public ContactSeraki Miyamoto
The University Tokyo Hospital Department of Psychosomatic Medicine
Outcome results
None listed